Marshall Wace’s Cellectis CLLS Stock Holding History

Marshall Wace’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41,112	Closed	-$130K	–	3229
2026 Q1	$130K	Sell	41,112 -137,361	-77%	-$527K	﹤0.01%	2866
2025 Q4	$864K	Buy	178,473 +168,038	+1,610%	+$702K	﹤0.01%	2006
2025 Q3	$29.7K	Buy	+10,435	New	+$27K	﹤0.01%	2765
2022 Q4	–	Sell	-108,744	Closed	-$249K	–	2981
2022 Q3	$249K	Sell	108,744 -5,697	-5%	-$17.3K	﹤0.01%	3009
2022 Q2	$324K	Sell	114,441 -31,757	-22%	-$112K	﹤0.01%	2995
2022 Q1	$663K	Buy	146,198 +140,714	+2,566%	+$775K	﹤0.01%	2643
2021 Q4	$44K	Buy	+5,484	New	+$53.9K	﹤0.01%	3582
2020 Q3	–	Sell	-38,472	Closed	-$685K	–	1611
2020 Q2	$685K	Buy	+38,472	New	+$586K	﹤0.01%	1108
2019 Q4	–	Sell	-16,243	Closed	-$169K	–	1733
2019 Q3	$169K	Sell	16,243 -33,241	-67%	-$447K	﹤0.01%	1311
2019 Q2	$772K	Buy	+49,484	New	+$884K	0.01%	992

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace's CLLS Position: Q2 2026 in Review

Marshall Wace sold out of Cellectis (CLLS) in Q2 2026, closing a stake of 41,112 shares — an estimated $130K sold.

Marshall Wace first reported a position in CLLS in Q2 2019 and held it in 10 quarters. The position peaked at $864K in Q4 2025. 27 funds tracked by Wall St. Rank hold CLLS as of Q2 2026.

Marshall Wace reported no remaining Cellectis position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 41,112 Cellectis shares in Q2 2026, an estimated $130K.
Marshall Wace first reported a position in Cellectis in Q2 2019 and held it in 10 quarters.
Marshall Wace's Cellectis position peaked at $864K in Q4 2025.
27 funds tracked by Wall St. Rank held Cellectis as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.